Fig. 3: NeoGATA3 is associated with altered ER-dependent transcriptional program.

a GSEA on the ranked list of genes differentially regulated in neoGATA3 tumors (n = 65) compared with all other tumors of the METABRIC ER + cohort (n = 1345). The “Hallmarks” collection of gene sets was interrogated. The graphs show the normalized enrichment score (NES) of the ten gene sets most significantly enriched among the upregulated (red) and the downregulated (blue) genes. FDR < 0.05 for all gene sets shown. b Gene expression data for the indicated cell cycle-related genes in the METABRIC ER + patients belonging to the three groups (WT n = 1189, neoGATA3 n = 66, OtherMut n = 155). c RPPA data from the TCGA cohort showing expression levels of the indicated proteins in the three tumor groups (WT n = 533, neoGATA3 n = 18, OtherMut n = 75). d Enrichment plots for genesets defined by Ross-Innes et al. comparing gene expression in tumors responding to endocrine therapy and tumors with poor response. GSEA was performed on genes differentially regulated in the neoGATA3 tumors from the METABRIC ER + cohort. e Enrichment plots for two progesterone-related genesets among the differentially expressed genes in the METABRIC neoGATA3 patients compared to all other METABRIC ER+. Mann–Whitney U test was used in (b, c). *P < 0.05, **P < 0.01.